The Latest
-
Getty Images via Getty Images
Can ‘reputational pull’ save biotech from pharma’s image problem?
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
-
Win McNamee via Getty Images
Pharma’s wins and losses in the budget bill
Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.
-
stock via Getty Images
COVID vax restrictions may not hamper uptake — but the market is still under pressure
If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space.
-
Permission granted by Novartis
ProfileThe former Wall Street analyst shaping Novartis’ big-picture strategy
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
-
Permission granted by Roche
The biggest obesity deals of 2025 so far
Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.
-
Permission granted by Daiichi Sankyo
With ADCs on the rise, drugmakers embrace a new oncology pillar
A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.
-
Anna Moneymaker via Getty Images
FDA’s Elsa AI is here, and the industry has questions
The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.
-
Stock via Getty Images
Biotech CEO confidence hits rock bottom amid policy shifts
A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.
-
BrasilNut1 via Getty Images
How leading oncology drugmakers set the stage for future advances
Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.
-
Courtesy of Sanofi
Sanofi to acquire Blueprint for up to $9.5B
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.
-
Thomas Lohnes via Getty Images
COVID’s remaining biotech contenders navigate a dwindling market
With policy and funding evolving, companies are being forced to rethink strategies.
-
Chip Somodevilla via Getty Images
The MAHA agenda won’t include expanding GLP-1 coverage — for now
Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.
-
Courtesy of AbbVie
AbbVie’s ADC win shows how pharma can break through in solid tumors
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
-
Stock via Getty Images
AI expertise is pharma’s next big hiring need — here’s what companies should look for
The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge.
-
iStock via Getty Images
With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon
Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.
-
Scott Olson via Getty Images
Lilly to buy pain drug developer SiteOne, challenging Vertex
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
-
Andrew Harnik via Getty Images
What’s next for Trump’s ‘most favored nation’ policy?
HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.
-
Chip Somodevilla via Getty Images
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.
-
Permission granted by Zealand Pharma
Q&A // First 90 DaysLilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
-
Stock via Getty Images
The placebo effect: How a new FDA rule could pile more strain onto vaccine developers
The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.
-
Justin Sullivan via Getty Images
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
-
Andrew Harnik via Getty Images
With the third round of Medicare price negotiations on the way, here’s how the policy is shifting
HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.
-
Stock via Getty Images
Tracking a moving target: Drugmakers brace for a looming tariff impact
With policies in flux, companies seek to be proactive and understand their supply chain.
-
Philip Pacheco via Getty Images
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.
-
Permission granted by Editas
Q&A // First 90 DaysA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.
